SCHEMBL16645540

SCHEMBL16645540

CCOC(=O)C1CCc2sc3nc(CCl)cc(=O)n3c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.41
APEX1 P27695 1/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 6/20 0.38
GRIN2A Q12879 5/20 0.38
GRIN1 Q05586 4/20 0.38
GRIA2 P42262 3/20 0.38
RXFP1 Q9HBX9 1/20 0.37
TP53 P04637 2/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16645450 0.80 GRIN2A (0.66) GRIN2AGRIN1GRIA2
SCHEMBL16637240 0.71 POLB (0.47) POLBAPEX1HTTTDP1L3MBTL1
SCHEMBL16637459 0.68 GRIN1 (0.47) POLBAPEX1HTTTDP1L3MBTL1
SCHEMBL10524670 0.67 ALDH1A1 (0.44) POLBHTTMEN1ALDH1A1KMT2A
SCHEMBL636590 0.66 L3MBTL1 (0.56) POLBAPEX1HTTTDP1L3MBTL1
SCHEMBL17971481 0.66 L3MBTL1 (0.49) POLBAPEX1HTTTDP1L3MBTL1
SCHEMBL16637603 0.65 GRIN1 (0.57) POLBAPEX1HTTTDP1L3MBTL1
SCHEMBL10998811 0.65 ALDH1A1 (0.54) POLBL3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL1155419 0.64 ALDH1A1 (0.49) HTTL3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL16636635 0.64 L3MBTL1 (0.53) POLBAPEX1HTTTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647731-B2 Thiazolopyrimidinones and methods of use thereof GENENTECH, INC. (US) 2020-05-12 US disclosed
EP-3055315-B1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2018-07-25 EP disclosed
EP-3055315-B1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2018-07-25 EP disclosed
US-9988400-B2 Thiazolopyrimidinones and methods of use thereof GENENTECH, INC. (US) 2018-06-05 US disclosed
US-9988400-B2 Thiazolopyrimidinones and methods of use thereof GENENTECH, INC. (US) 2018-06-05 US disclosed
US-9988400-B2 Thiazolopyrimidinones and methods of use thereof GENENTECH, INC. (US) 2018-06-05 US disclosed
US-20160222033-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-08-04 US disclosed
US-20160222033-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-08-04 US disclosed
WO-2015052226-A1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647731-B2 Thiazolopyrimidinones and methods of use thereof TPMT, THPO, CYP11B2 POLB 3179/4885APEX1 2377/4885HTT 657/4885
US-20160222033-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF TPMT, THPO, CYP11B2 POLB 3179/4885APEX1 2377/4885HTT 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.